Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW28012 in Advanced Solid Tumors
NCT06799637Phase 2Recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of xnw28012 in solid tumor, pancreatic cancer (PC), ovarian cancer and 2 more, sponsored by Evopoint Biosciences. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 1 year and Antitumor efficacy of XNW28012 at the recommended Part 2 dose at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
xnw28012
03
Conditions
solid tumorpancreatic cancer (PC)ovarian cancerCervical Cancer (CC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06799637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799637.